Wednesday, July 03, 2024
Pulnovo Medical Limited, a global leader in devices for treating pulmonary hypertension and heart failure, has announced the successful enrollment of the first two patients in its global multicenter clinical trial for percutaneous pulmonary denervation (PADN) therapy.
This therapy targets pulmonary hypertension linked to left-sided heart disease. This milestone occurred at Centro Hospitalar Universitário de Lisboa Central - Hospital de Santa Marta in Portugal, initiating the international rollout of Pulnovo Medical's innovative product.
The procedure went smoothly, with the instruments proving user-friendly and effective. The Portuguese medical team praised the PADN technology's safety and efficacy, supported by extensive data.
Clinical results indicated promising outcomes, with advanced product design and precise control algorithms ensuring stable energy output and successful surgical results.
"PADN technology shows significant potential in treating pulmonary hypertension associated with left-sided heart disease.
They are thrilled to be the first in Europe to participate in this global clinical trial. Our team is confident in this project and looks forward to offering more treatment options to European patients with pulmonary hypertension.
PADN brings new hope to those suffering from this condition."
"The PADN global multicenter clinical trial is a key initiative for us, focusing on innovative cardiovascular treatments.
PADN has tremendous potential and prospects. The results from the first international application of PADN demonstrate its global relevance. They will continue to promote our global business and support education around PADN technology."
"Proud of completing the first enrollment in the European multicenter PADN clinical trial in Portugal, which accelerates our technology's global progress.
They will continue to support PADN's worldwide application, benefiting more patients with this innovative therapy."
Source: prnewswire.com
